Result of AGM

AstraZeneca PLC
11 April 2024
 

11 April 2024 1730 BST

 

Results of Annual General Meeting held on 11 April 2024

 AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 11 - 14 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

 

Resolution

Votes for

% of votes cast

Votes against

% of votes cast

Votes cast in total

Total votes cast as a % of issued share capital

Votes withheld

1

To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2023

1,205,690,871

99.88

1,470,816

0.12

1,207,161,687

77.87%

9,700,968

2

To confirm dividends

1,215,177,590

99.94

790,189

0.06

1,215,967,779

78.44%

894,978

3

To reappoint PricewaterhouseCoopers LLP as Auditor

1,208,377,872

99.36

7,843,545

0.64

1,216,221,417

78.45%

642,048

4

To authorise the Directors to agree the remuneration of the Auditor

1,215,717,786

99.98

279,816

0.02

1,215,997,602

78.44%

722,222

5a

To re-elect Michel Demaré as a Director

1,197,325,871

98.49

18,416,788

1.51

1,215,742,659

78.42%

1,120,559

5b

To re-elect Pascal Soriot as a Director

1,206,729,787

99.26

9,036,742

0.74

1,215,766,529

78.42%

1,098,706

5c

To re-elect Aradhana Sarin as a Director

1,212,225,383

99.71

3,509,122

0.29

1,215,734,505

78.42%

1,129,532

5d

To re-elect Philip Broadley as a Director

1,197,937,103

98.54

17,773,671

1.46

1,215,710,774

78.42%

1,153,360

5e

To re-elect Euan Ashley as a Director

1,213,332,278

99.80

2,375,199

0.20

1,215,707,477

78.42%

1,156,567

5f

To re-elect Deborah DiSanzo as a Director

1,215,396,504

99.97

318,525

0.03

1,215,715,029

78.42%

1,149,106

5g

To re-elect Diana Layfield as a Director

1,215,424,019

99.98

292,514

0.02

1,215,716,533

78.42%

1,147,602

5h

To elect Anna Manz as a Director

1,215,297,866

99.97

417,067

0.03

1,215,714,933

78.42%

1,149,091

5i

To re-elect Sheri McCoy as a Director

1,158,846,767

95.32

56,874,293

4.68

1,215,721,060

78.42%

1,142,920

5j

To re-elect Tony Mok as a Director

1,215,346,936

99.97

346,157

0.03

1,215,693,093

78.42%

1,170,931

5k

To re-elect Nazneen Rahman as a Director

1,191,449,316

98.59

16,988,178

1.41

1,208,437,494

77.95%

8,426,242

5l

To re-elect Andreas Rummelt as a Director

1,215,395,253

99.97

314,359

0.03

1,215,709,612

78.42%

1,154,412

5m

To re-elect Marcus Wallenberg as a Director

947,479,100

77.93

268,252,536

22.07

1,215,731,636

78.42%

1,132,416

6

To approve the Annual Report on Remuneration for the year ended 31 December 2023

1,158,470,360

95.32

56,835,406

4.68

1,215,305,766

78.40%

1,558,941

7

To approve the Directors' Remuneration Policy

 

761,702,826

64.43

420,514,520

35.57

1,182,217,346

76.26%

34,645,873

8

To approve amendments to the AstraZeneca Performance Share Plan 2020

 

769,577,451

65.34

408,204,003

34.66

1,177,781,454

75.97%

39,083,170

9

To authorise limited political donations

1,184,223,861

98.00

24,219,787

2.00

1,208,443,648

77.95%

8,278,265

10

To authorise the Directors to allot shares

1,129,625,915

92.94

85,836,406

7.06

1,215,462,321

78.41%

1,259,562

11

To authorise the Directors to disapply pre-emption rights

1,044,559,011

85.95

170,708,848

14.05

1,215,267,859

78.39%

1,454,048

12

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments

997,629,834

82.33

214,143,713

17.67

1,211,773,547

78.17%

4,948,031

13

To authorise the Company to purchase its own shares

1,205,828,976

99.23

9,306,860

0.77

1,215,135,836

78.38%

1,585,923

14

To reduce the notice period for general meetings

1,131,157,449

93.07

84,269,754

6.93

1,215,427,203

78.40%

1,294,801

 

A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 Statement in connection with resolutions 5m, 7 and 8

AstraZeneca is pleased that all resolutions were supported at today's Annual General Meeting. In particular, the Board thanks the majority of our shareholders who have supported the Remuneration Policy (the Policy) and will continue to engage with our shareholders and the proxy advisors to explain our need for global benchmarks and pay for performance, which is driven by the Policy.

We will publish an update on the engagement with shareholders on resolutions 5m, 7 and 8 and on any action taken as a result within six months of today's AGM, in accordance with the UK Corporate Governance Code.

Issued capital

As at 9 April 2024, the number of issued shares of the Company was 1,550,231,084 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings